Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.

Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.

High-dose valaciclovir at up to 8 g/day has been shown to be effective in prophylaxis against cytomegalovirus (CMV) disease in renal transplant recipients. We report our experience with low-dose valaciclovir prophylaxis of up to 3 g/day, adjusted to creatinine clearance. A group of patients at high...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Reddy, S, Handa, A, Tan, L, Devaney, A, Hughes, D, Mason, P, Friend, P, Darby, C
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	2003

Gelijkaardige items

Comparison between valganciclovir and aciclovir/valaciclovir for CMV prophylaxis in pediatric renal transplantation
door: M Fila, et al.
Gepubliceerd in: (2015-01-01)

Prophylaxis of Cytomegalovirus in Renal Transplant Recipients
door: Allan S MacDonald, et al.
Gepubliceerd in: (1993-01-01)

Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients.
door: Hughes, D, et al.
Gepubliceerd in: (2008)

Resistant cytomegalovirus infection in renal transplant recipients
door: Benjamin Pei Zhi Cherng, et al.
Gepubliceerd in: (2015-12-01)

Tuberculosis in Renal Transplant Recipients: The Evidence for Prophylaxis
door: Currie, A, et al.
Gepubliceerd in: (2010)

Prevention of Congenital Cytomegalovirus Infection: Review and Case Series of Valaciclovir versus Hyperimmune Globulin Therapy
door: Giovanni Nigro, et al.
Gepubliceerd in: (2023-06-01)

Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience
door: Linda A. Selvey, et al.
Gepubliceerd in: (2017-07-01)

Effectiveness of valacyclovir prophylaxis against the occurrence of cytomegalovirus infection in kidney transplant recipients
door: Woo Yeong Park, et al.
Gepubliceerd in: (2020-03-01)

Coinfection of BK virus and cytomegalovirus in renal transplant recipients
door: Rudreshwar Prabakaran, et al.
Gepubliceerd in: (2017-01-01)

Pitfalls in Valganciclovir Prophylaxis Dose Adjustment Based on Renal Function in Kidney Transplant Recipients
door: Nathalie Hammer, et al.
Gepubliceerd in: (2024-05-01)

Lymphocyte subpopulations during cytomegalovirus disease in renal transplant recipients
door: S.M. Castro, et al.
Gepubliceerd in: (2003-06-01)

Cytomegalovirus disease in a renal transplant recipient: the importance of pre-transplant screening of the donor and recipient
door: Ahmed H Mitwalli, et al.
Gepubliceerd in: (2013-01-01)

A single-centre observational study comparing the impact of different cytomegalovirus prophylaxis strategies on cytomegalovirus infections in kidney transplant recipients
door: Mabel Si Hua Tan, et al.
Gepubliceerd in: (2021-06-01)

Cytomegalovirus infection in renal transplant recipients diagnosed by nested-PCR
door: V.H. Aquino, et al.
Gepubliceerd in: (2001-01-01)

Cytomegalovirus in renal transplant recipients from living donors with and without valganciclovir prophylaxis and with immunosuppression based on anti-thymocyte globulin or basiliximab
door: Jorge Andrade-Sierra, et al.
Gepubliceerd in: (2021-06-01)

Rabdomiolisis asociada al tratamiento con valaciclovir
door: Héctor Enríquez Gómez, et al.
Gepubliceerd in: (2012-03-01)

Efficacy of Low Dose Valganciclovir Prophylaxis for Cytomegalovirus Infection in Kidney Transplantation
door: Ümit Özçelik, et al.
Gepubliceerd in: (2020-01-01)

Cytomegalovirus infection in transplant recipients
door: Luiz Sergio Azevedo, et al.
Gepubliceerd in: (2015-07-01)

Molecular detection and genotyping of Human Cytomegalovirus in kidney transplant recipients under ganciclovir prophylaxis in Iran
door: Farzane Behnezhad, et al.
Gepubliceerd in: (2022-07-01)

PHARMACOECONOMIC BENEFITS OF CYTOMEGALOVIRUS INFECTION PROPHYLACTIC STRATEGY FOR RENAL TRANSPLANT RECIPIENTS
door: V. V. Ryazhenov, et al.
Gepubliceerd in: (2011-06-01)

Cytomegalovirus ischemic colitis and transverse myelitis in a renal transplant recipient
door: Imen Gorsane, et al.
Gepubliceerd in: (2013-01-01)

Evaluation of diagnostic tests for cytomegalovirus active infection in renal transplant recipients
door: Rodrigo Fontanive Franco, et al.

Cytomegalovirus Infection in Pediatric Renal Transplant Recipients: A Single Center Experience
door: Mi Jin Kim, et al.
Gepubliceerd in: (2017-10-01)

Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
door: Diana D. Wong, et al.
Gepubliceerd in: (2022-06-01)

Cytomegalovirus Infection in Kidney Transplant Recipients
door: Dino Šisl, et al.
Gepubliceerd in: (2021-04-01)

Cytomegalovirus DNAemia in kidney transplant recipients after cessation of standard antiviral prophylaxis; estimated rate on Thai cases and implication on efficacy of prophylaxis
door: Won Sriwijitalai, et al.
Gepubliceerd in: (2019-05-01)

Direct visualisation of cytomegalovirus-specific CD8+ T cells in renal transplant recipients.
door: Hilton, R, et al.
Gepubliceerd in: (2002)

Cytomegalovirus infection and unusual early graft dysfunction in a renal transplant recipient
door: Suzan Sanavi, et al.
Gepubliceerd in: (2009-01-01)

Outcome of renal transplant recipients with cytomegalovirus and BK polyomavirus co-infection nephropathy
door: Anupma Kaul, et al.
Gepubliceerd in: (2018-01-01)

Postsurgical skin ulcers caused by cytomegalovirus vasculopathy in a renal transplant recipient
door: Shikha Rao, MD, et al.
Gepubliceerd in: (2020-07-01)

Prevalence of nonmalignant cutaneous disease in renal transplant recipients
door: Lally, A, et al.
Gepubliceerd in: (2006)

Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy
door: Restelli U, et al.
Gepubliceerd in: (2019-05-01)

Efficacy of valaciclovir in preventing herpes zoster in patients receiving anifrolumab
door: Zahir Amoura, et al.
Gepubliceerd in: (2025-01-01)

Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient
door: Susanne Jung, et al.
Gepubliceerd in: (2019-05-01)

Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation
door: Kaiwen Chen, et al.
Gepubliceerd in: (2018-08-01)

Low dose thymoglobulin versus basiliximab in cytomegalovirus positive kidney transplant recipients: Effectiveness of preemptive cytomegalovirus modified strategy
door: Camilo Montero, et al.
Gepubliceerd in: (2023-03-01)

Low dose thymoglobulin versus basiliximab in cytomegalovirus positive kidney transplant recipients: Effectiveness of preemptive cytomegalovirus modified strategy
door: Camilo Montero, et al.
Gepubliceerd in: (2023-03-01)

Prevention and Treatment of Cytomegalovirus Infection in Transplant Recipients
door: Jutta K Preiksatis
Gepubliceerd in: (1993-01-01)

Comparison of prophylactic versus preemptive treatments in the management of cytomegalovirus infection in renal transplant recipients
door: Cengiz Karaçin, et al.
Gepubliceerd in: (2020-05-01)

Cutaneous involvement by cytomegalovirus in a renal transplant recipient as an indicator of severe systemic infection
door: Antonielle Borges Faria Neumann, et al.
Gepubliceerd in: (2016-02-01)